In 2014, the FDA approved blinatumomab, a BiTEtargeting CD19 and CD3, in the treatment of relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (B-ALL) [10]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.